Medicines Co skin infection antibiotic meets trial goal

(Reuters) - Medicines Co said a late-stage trial of its experimental drug for bacterial skin infections met the main study goal of stopping the infection from spreading and the absence of fever, sending the company's shares up 9 percent. The drug oritavancin was being tested for the treatment of acute bacterial skin and skin structure infections (ABSSSI), caused by susceptible gram-positive bacteria, including a highly contagious drug-resistant bacteria. The trial, named Solo-1, showed that oritavancin was non-inferior to the standard-of-care antibiotic vancomycin in its efficacy. ... via Health News Headlines - Yahoo! News Read More Here..

For a Free Step By Step Guide for Dating Dos and Don'ts check http://end2endwebs.com

Lake forest health and fitness http://healthandfitness1blog.blogspot.com/2012/12/medicines-co-skin-infection-antibiotic.html